Mobile website
Archive > Volume 24 Issue 9 > 2017,24(9):1006-1009. DOI:10.3872/j.issn.1007-385X.2017.09.014 Prev Next
Clinical Research
Clinical efficacy of axitinib and sorafenib as first-line treatment for advanced re-nal cell carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To compare the clinical efficacy of axitinib and sorafenib as first-line treatment for advanced renal cell carcinoma, and to explore whether axitinib could be used as a preferred first-line drug for advanced renal cell carcinoma. Methods: Sixty patients with advanced renal cell carcinoma from Haikou Municipal Hospital were enrolled in this study and divided into experimental group (n=30) and control group (n=30) according to a random number table. The experimental group received axitinib treatment and the control group received sorafenib treat-ment. Disease control rate (DCR), objective response rate (ORR), progression free survial (PFS), overall survival (OS), and adverse effects were evaluated and compared between two groups. Results: All patients in the two groups completed the experiment. There was no difference between the experimental group and the control group in DCR (83.33% vs 80.00% , P>0.05) and ORR (20.00% vs 20.00% , P>0.05). Significant difference in median PFS was found between the two groups (12.8 months of experimental group vs 10.1 months of control group, P<0.05);however, there was no significant difference in the median OS between two groups (22.2 months vs 22.8 months, P>0.05). The incidence of adverse reactions in the two groups was similar, mainly including hypertension, systemic re-actions, hand foot skin syndrome, digestive system reaction and liver function damage (P>0.05). No serious ad-verse effects were observed in both groups. Conclusion: Compared with sorafenib, axitinib significantly prolonged the median PFS in patients with advanced renal cell carcinoma, although the diseasecontrol rate, objective efficien-cy, overall survival, and adverse effects of two treatment regimen were comparable. Axitinib, the molecular targeted agent, can be used as a preferred first-line therapy for advanced renal cell carcinoma.
Keywords:
Project Supported:
Clc Number:
